US Buys Nearly Full Stock Of Covid-19 Drug Remdesivir

US, the worst-hit nation by coronavirus pandemic as it recorded more than 2.5 million cases of the coronavirus is buying nearly the entire global stock of Remdesivir from its US based manufacturer Gilead.

The US Department, in a press statement of Health and Human Services, announced that it will be buying up virtually the entire produced stock of Remdesivir from manufacturer Gilead till September.

‘’To the extent possible, we want to ensure that any American patient who needs Remdesivir can get it. The Trump administration is doing everything in our power to learn more about life-saving therapeutics for COVID-19 and secure access to these options for the American people,” said the US health and human services secretary, Alex Azar.

Remdesivir is an antiviral drug which works by copying the genetic make-up of the coronavirus, the RNA and slows down replication. It is known to reduce the COVID-19 symptoms in 4-5 days and is the first authorized therapeutic treatment for it.

The drug is also believed to be most effective in treating patients earlier in the course of disease than dexamethasone, which reduced deaths in patients requiring supportive oxygen and those on a ventilator.